Want to see VXRT full AI Analyst Report?
VXRT Stock Chart & Stats
$0.50
-$0.04(-9.07%)
At close: 4:00 PM EDT
$0.50
-$0.04(-9.07%)
Day’s Range― - ―
52-Week Range$0.31 - $0.84
Previous CloseN/A
Volume443.29K
Average Volume (3M)328.14K
Market Cap
$139.63M
Enterprise Value$95.07
Total Cash (Recent Filing)$63.98M
Total Debt (Recent Filing)$7.81M
Price to Earnings (P/E)3.6
Beta1.75
Next Earnings
Oct 29, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding242,835,360
10 Day Avg. Volume319,706
30 Day Avg. Volume328,137
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.92
Price to Sales (P/S)0.34
P/FCF Ratio10.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.32
Revenue Forecast (FY)$200.45M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase II COVID-19 vaccine trial is progressing rapidly, with the sentinel cohort enrollment ahead of schedule, indicating strong advancement in the study.
Growth PotentialVaxart's efforts to refine its norovirus program address a significant unmet need in a market with no approved vaccines, showcasing potential for growth and innovation.
Regulatory MilestonesVXRT's norovirus oral vaccine unique competitive position to further benefit from upcoming regulatory milestones.
Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
Vaxart News
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $0.30 and its highest was $0.84 in the past 12 months.
What is Vaxart Inc’s market cap?
Vaxart Inc’s market cap is $139.63M.
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Vaxart Inc’s earnings last quarter?
Vaxart Inc released its earnings results on Aug 06, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.06.
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Overvalued.
Does Vaxart Inc pay dividends?
Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -0.17.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 242,835,360 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Vaxart Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -3.509%.
Which hedge fund is a major shareholder of Vaxart Inc?
Currently, no hedge funds are holding shares in VXRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxart Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
VXRT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $6.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.67%
Trailing 12-Months
Company Description
Vaxart Inc
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
VXRT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of encouraging clinical and operational developments alongside material financial and timing risks. Key positives include a clean 12‑month safety signal in the sentinel cohort, BARDA’s $29 million contract modification enabling deeper analyses, a fully enrolled ~5,000‑participant main cohort with topline expected H1 2027, governance improvements, and a defined cash runway with flexible financing options. Offsetting these are a ~31.5% year‑over‑year revenue decline, a limited cash runway into Q2 2027 that creates timing pressure for funding or partner opt‑ins, reliance on BARDA for data release timing, uncertainty around the norovirus partnership and development timelines, and that the sentinel cohort was not powered to demonstrate efficacy (symptomatic case counts were similar between arms). On balance, positives (safety readout, BARDA support, large main cohort enrollment, governance actions) are meaningful but are matched by significant near‑term financing and commercialization uncertainties; the overall tone is constructive but cautious.View all VXRT earnings summariesTechnical Analysis
Atossa Therapeutics
―
Karyopharm Therapeutics
―
Pliant Therapeutics
―
―
Kalaris Therapeutics
―
Ownership Overview
2.67% Insiders
<0.01% Mutual Funds
0.02% Other Institutional Investors
97.31% Public Companies and
Individual Investors